Navigation Links
GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine
Date:6/23/2011

ATLANTA, June 23, 2011 /PRNewswire/ -- GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, announced today the opening of a third site for testing the therapeutic potential of its HIV/AIDS vaccine.  The Los Angeles-based AIDS Research Alliance (ARA) will join with two existing members of GeoVax's clinical trial site team: the AIDS Research Consortium of Atlanta and the Alabama Vaccine Research Clinic at the University of Alabama at Birmingham. The ARA is the nation's only independent, nonprofit HIV/AIDS research institute.

The therapeutic trial is the first trial to test the GeoVax vaccine as a possible treatment for HIV-infected people.  Studies with simian prototypes of the vaccine in infected non-human primates have demonstrated the ability to control viral replication in the absence of anti-viral drugs.  The clinical trial in HIV-infected patients will test safety, vaccine-induced immune responses and the ability of the vaccine to control viral replication.

"We are excited to expand our therapeutic trial team to include the AIDS Research Alliance," said Mark Newman, PhD, Vice President of Research and Development at GeoVax.  "They are a group with a mission that parallels that of GeoVax, developing a vaccine to prevent infection by HIV and developing better treatments for those who become infected."

Dr. Stephen Brown, ARA's medical director, said, "The ARA leadership is very familiar with the GeoVax HIV vaccine products through our involvement with the HVTN, and we are excited to participate in this clinical trial.  The development of new products and approaches that build upon existing antiretroviral drugs regimens would be a major breakthrough."

To be eligible for the study, potential volunteers must have started antiretroviral therapy within 18 months of a negative HIV antibody test and must remain on stable antiretrovira
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Article by GeoVax Labs CSO Featured in The Scientist
2. GeoVax Labs Announces Availability of 2010 Annual Report and Presidents Letter to Stockholders
3. GeoVax Labs, Inc. Announces First Quarter Financial Results
4. GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results
5. GeoVax Labs CSO Dr. Harriet L. Robinson to be Honored at 2011 Georgia Bio (GaBio) Community Awards Ceremony
6. GeoVax Labs Inc. Announces Results of 2010 Annual Stockholders Meeting
7. GeoVax Labs, Inc. Reports Data on Prototype Adjuvant - Supplemented HIV Vaccine Tested in Preclinical Animal Studies
8. GeoVax Labs, Inc. Celebrates 21st World AIDS Day With Continued Clinical Trial Progress
9. GeoVax Labs, Inc. Moving Operations to Smyrna, Georgia
10. Formatech, Inc. to Donate Services to Formulate and Fill GeoVax Labs, Inc. HIV/AIDS Vaccine Under Its Fillanthropy(TM) Program
11. Encouraging HIV/AIDS Vaccine Trial Results Support GeoVax Labs, Inc. Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... DUBLIN , May 19, 2015 Research and ... addition of the "Global Cell Therapy Market Outlook ... Utilization of cell therapy in tissue and regenerative medicine ... are no other options which could help in the ... in this segment but they are unable to form ...
(Date:5/20/2015)... 2015  Health eCareers, the healthcare industry,s online ... job seekers looking for the flexibility of short-term ... and online tool dedicated exclusively to temporary and ... SHIFT enables employers to quickly find and hire ... diem and other temporary positions, eliminating the time ...
(Date:5/20/2015)... 20, 2015  Haemonetics Corporation (NYSE: HAE ) ... CEO, will present at The Jefferies 2015 Global Healthcare ... June 1 st , 2015 at 8:30am Eastern time.  ... presentation live via webcast at: http://wsw.com/webcast/jeff88/hae ... HAE ) is a global healthcare company dedicated to ...
(Date:5/20/2015)... 19, 2015 Research and Markets ... the "Bone Morphogenetic Proteins Market (Types : ... and Oral - Maxillofacial) - Global Industry Analysis, ... 2022" report to their offering. ... based on the types of recombinant BMPs, applications, ...
Breaking Biology Technology:Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 2Health eCareers Launches SHIFT Mobile and Online Tool to Match Healthcare Employers with Temporary Job Seekers 3Global Bone Morphogenetic Proteins Market Industry Analysis 2014 - 2022 2
... hand-held devices from mobile phones and cameras to music ... on to develop memory formats that can satisfy the ever-growing ... The University of Nottingham are now exploring ways of exploiting ... and compact memory cell that uses little power and writes ...
... KANSAS CITY, Mo., Nov. 11 An investor group ... based developer and manufacturer of,diagnostic products whose shares are ... NASDAQ, has initiated a campaign for,conversion of company ADRs ... shareholders to consider a change in the board., ...
... 11 In a presentation,today at the American ... Baylor College of Medicine have presented,data from the ... the genetic risk factor on chromosome 9p21,detected by ... to,improve the assessment of individual risk of future ...
Cached Biology Technology:Miniaturizing memory: Taking data storage to the molecular level 2Major Independent Study Underscores Utility of deCODE MI(TM) for Better Predicting Risk of Heart Attack, Informing Statin Therapy 2Major Independent Study Underscores Utility of deCODE MI(TM) for Better Predicting Risk of Heart Attack, Informing Statin Therapy 3Major Independent Study Underscores Utility of deCODE MI(TM) for Better Predicting Risk of Heart Attack, Informing Statin Therapy 4
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, a ... start of a new Phase III double blind, randomized, ... novel formulation, CM-AT, on all children ages 3-8 with ... FDA Phase III double blinded clinical trial for CM-AT ... levels of the digestive enzyme chymotrypsin. This new trial ...
(Date:5/8/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), the ... of the executive management team will present at the following ... and Telecom Conference Date: May 18, 2015 Time: ... MA Cowen and Company Technology, Media ... Location: The New York Palace Hotel, New York, ...
(Date:5/6/2015)... LifeBEAM, a developer of bio-sensing technology, and ... that they will expand their partnership in bio-sensing sports ... helmet and the first joint project between the two ... order to give cyclists more style choices and meet ... Lazer announced their plan to release a new generation ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... announced measures to fight the mountain pine beetle and ... Columbia. The Federal Mountain Pine Beetle Program will provide ... infestation and assist in efforts to slow the infestation's ... to the economy and the communities of British Columbia," ...
... Plant poisoning is a significant problem around the world. ... for approximately ten percent of the annual calls to ... need for a useful guide to the harmful potential ... portable, comprehensive information to the toxic plants encountered ...
... of the 1980s was greatly exaggerated, cocaine use ... impairments -- attention deficits, learning disabilities and emotional ... at the Vanderbilt Kennedy Center for Research on ... and neurological problems associated with prenatal exposure to ...
Cached Biology News:Canada's new government invests $200M in the fight against the mountain pine beetle 2Illuminating the dark side of plants 2Prenatal cocaine's lasting cellular effects 2Prenatal cocaine's lasting cellular effects 3
The DNA DipStick Kit is ideal for estimating nucleic acid concentrations and approximate yields. Works with ss- and ds-DNA, RNA, and oligonucleotides at concentrations as low as 0.1 ng/l....
... The NEW HandyStep electronic from BRAND ... pipetting. It is the only electronic, ... standard syringe tips, including BRAND PD-Tip ... Plus, Fisherbrand Dispenser Tips,and VWRbrand Combi-Syringes. ...
The pYES2 vector is designed for native expression of your protein of interest in S. cerevisiae. It contains the URA3 gene for selection in yeast and 2 origin for high-copy maintenance....
Each 72-well MiniTray is low profile, with lid. Conical well shape, 10 l....
Biology Products: